Skip to main content
letter
. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4

Fig. 2. Survival analysis.

Fig. 2

A Progression-free survival (PFS) of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CEOP and R-CHOP. Kaplan–Meier curves showing significant inferior 4-year PFS in patients with DLBCL treated with R-CEOP (p = 0.03). B Overall survival (OS) of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CEOP and R-CHOP. Kaplan–Meier curves showing a significant inferior 4-year OS in patients with DLBCL treated with R-CEOP (p = 0.05). C Relative survival (RS) of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CEOP and R-CHOP. Kaplan–Meier curves showing no significant difference in 4-year RS in patients with DLBCL treated with R-CEOP (p = 0.77).